A carregar...
GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy
BACKGROUND: The clinical trials emerged centromere protein E inhibitor GSK923295 as a promising anticancer drug, but its function in hepatocellular carcinoma (HCC) remain needs to be fully elucidated, especially as chemotherapy after hepatectomy for liver tumors. We aimed to describe anti-HCC activi...
Na minha lista:
| Publicado no: | Chin Med J (Engl) |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6595801/ https://ncbi.nlm.nih.gov/pubmed/30681497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000053 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|